Msci Inc vs Nuwellis Inc — how do they compare? Msci Inc trades at $562 (market cap $40.84B), while Nuwellis Inc trades at $1.48 (market cap $542.80K). The key difference: Msci Inc is far larger — about 75239.5× Nuwellis Inc's market cap, and Msci Inc pays a 1.46% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals.
| MSCI | NUWE | |
|---|---|---|
Market Cap | $40.84B | $542.80K |
Sector | Financials | Technology |
52-Week High | $643.83 | $220.50 |
52-Week Low | $511.84 | $1.42 |
Enterprise Value | $47.00B | -$1.27M |
Dividend Yield | 1.46% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
NUWE trades at $1.49, down 8.59% over the past day, with a bearish technical outlook. The company reported a net loss of $17.52M in 2025, with a negative net income margin of -217.22%, though it has shown revenue growth and recent strategic expansions in pediatric care. A recent 35:1 reverse stock split was executed on June 26, 2026.
The outlook remains high-risk due to persistent losses and cash burn, but growth initiatives and new product development offer potential. Key risks include execution challenges and dependence on financing. Analyst sentiment is mixed, with a 50% buy and 50% hold rating among covered analysts.
Trailing returns across standard periods
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →